Showing results (331-340 of 382) with videos related to
Sort By:
Pageof 39
Journal for Immunotherapy of Cancer|June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.The Prostate|June 6, 2015
Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention TrialDanyelle A Winchester, Cathee Till, Phyllis J Goodman, et al.Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.The Journal of Clinical Investigation|February 5, 2020
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer targetZachary T Freeman, Thomas R Nirschl, Daniel H Hovelson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid TumorsEmerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2020
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate CancerAleksandar Z Obradovic, Matthew C Dallos, Marianna L Zahurak, et al.The American Journal of Pathology|March 27, 2018
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate CancerMichael C Haffner, Gunes Guner, Diana Taheri, et al.Cancer Cell|November 3, 2023
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancerJessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2026
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder CancerAndrew B Katims, Charlie White, Syed Muneeb Alam, et al.The Journal of Urology|August 26, 2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialK Kent Chevli, Neal D Shore, Andrew Trainer, et al.Pageof 39